Edition:
United Kingdom

Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

3.57USD
17 Aug 2018
Change (% chg)

$0.11 (+3.18%)
Prev Close
$3.46
Open
$3.49
Day's High
$3.57
Day's Low
$3.49
Volume
700
Avg. Vol
4,566
52-wk High
$6.64
52-wk Low
$2.28

Chart for

About

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding... (more)
No analyst recommendations are available for .

Overall

Beta: -0.08
Market Cap(Mil.): $15.39
Shares Outstanding(Mil.): 4.83
Dividend: --
Yield (%): --

Financials

  KZIA.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -3.91 -- --
ROI: -33.03 1.78 14.61
ROE: -36.01 3.28 16.33

BRIEF-Kazia Receives FDA Orphan Designation For Gdc-0084

* KAZIA THERAPEUTICS LTD - PHASE II CLINICAL STUDY OF GDC-0084 IS ANTICIPATED TO PROVIDE AN INITIAL DATA READ-OUT IN EARLY CALENDAR 2019 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

23 Feb 2018

BRIEF-Kazia Therapeutics Receives U.S. FDA Orphan Designation For Drug

* ‍ RECEIVES U.S. FDA ORPHAN DESIGNATION FOR DRUG FOR TREATMENT OF FORM OF PRIMARY BRAIN CANCER​ Source text for Eikon: Further company coverage:

23 Feb 2018

Competitors

Earnings vs. Estimates